Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse ...

Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy instead of tariffs to promote domestic pharma manufacturing.

Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.

Repatha generated revenues of $656.0 million ... Zepbound and Wegovy, which are weekly injections. In March, Amgen initiated two phase III studies on MariTide in obesity as part of its ...

Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent ... or pain/tenderness at the injection site; flu or flu-like symptoms; diarrhea; muscle pain; muscle ...

and Sanofi/Regeneron’s Repatha (alirocumab) – but these require subcutaneous injection every two to four weeks. Sales of both the commercially available antibodies have failed to live up to ...

Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...